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Kidney cancer accounts for approximately 2% of all cancers worldwide, with renal cell carci-
noma being the most common form and this report is focused on renal cell carcinoma.
Globally, the incidence and mortality rates are increasing by 2–3% per decade. Kidney cancer
is less common in Asia compared with the West. Cigarette smoking, obesity, acquired cystic
kidney disease and inherited susceptibility are known risk factors for kidney cancer. The
National Comprehensive Cancer Network Guidelines recommend surgical excision as first line
of treatment for Stage I, II or III kidney cancer patients and Stage IV patients with resectable
tumours. Immunotherapy has a 20-year history in treatment of metastatic kidney cancer. High-
dose interleukin-2 (IL–2) is administered in some countries, whereas low-dose IL-2 and
interferon-alpha (IFN-a) are popular in Japan. Molecular-targeted drugs, including sunitinib,
bevacizumab and sorafenib, are being used for previously untreated and refractory patients.
Asian and non–Asian populations have shown large differences in the incidences of adverse
events with sorafenib and sunitinib. Consensus Statement: Kidney cancer is relatively uncom-
mon in Asia compared with the West, but its incidence is increasing in more developed Asian
nations. Guidelines from the National Comprehensive Cancer Network , etc., for treating meta-
static renal cell carcinoma are based on Phase III clinical trials conducted primarily in Western
patients. Targeted therapies are now becoming primary recommendations, but efficacy/toxicity
data from Asian patients are lacking. Some drugs cause adverse effects in Asians because
their recommended dosages are optimal for Caucasians but may be too high for Asians.
Further research is necessary to develop optimal treatment strategies for Asians.
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THE WORKING REPORT UROLOGICAL
CANCER
Kidney Cancer presentation was divided into ﬁve chapters:
epidemiology, risk factors, treatment of local disease, sys-
temic therapy for metastatic disease and the Working
Group’s consensus statement. The consensus statement is
focused on renal cell carcinoma (RCC) and was prepared on
the basis of evidence from data published in peer-reviewed
journals or texts, or abstracts from renowned international
congresses, such as AUA, ASCO, ESMO and EAU.
EPIDEMIOLOGY
Kidney cancer accounts for approximately 2% of all cancers
worldwide. RCC is the most common form of kidney cancer
(1). The rates of incidence vary more than 10-fold among
regions (2). The more-developed countries show higher inci-
dences of kidney cancer in both males and females, whereas
the incidences in both sexes are lower in the less-developed
countries. Higher incidences of kidney cancer are seen in
Europe, North America, Argentina, Oceania and Japan.
Lower incidence rates are seen in Africa and other Asian
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countries. Japan shows higher incidences than those seen in
other Asian countries (3). Globally, the incidence and mor-
tality rates for kidney cancer are increasing by 2–3% per
decade (Table 1). The incidence of kidney cancer in each of
three global regions, Asia, Europe and the USA, is increas-
ing with time. Although the reason is unclear, the incidence
is decreasing in Sweden (4).
There are racial disparities in RCC incidence and survival.
Data from the California Cancer Registry show a lower inci-
dence and higher survival among Asians and Paciﬁc
Islanders compared with whites, blacks and Hispanics.
However, regardless of race, the incidence is increasing (5).
In Japan, the percentage of incidental kidney tumours has
been increasing. This may be due to the increased prevalence
of screening and imaging systems. However, and unfortu-
nately, in Malaysia and other developing countries sympto-
matic tumours still account for 80–90% of kidney tumour
cases (expert opinion).
Data from Keio University (Tokyo, Japan) for the period
from 1985 to 2003 revealed the characteristics of RCC in
Japan (Table 2) (6). A total of 545 patients underwent
radical or partial nephrectomy. Three-quarters of the patients
were male, and the mean age at diagnosis was 58 years. The
mean tumour size was 4.8 cm. Radical surgery was per-
formed for 82% and nephron-sparing surgery was performed
for 18% of the patients. Adjuvant immunotherapy, such as
IFN-a or IL–2, was administered to 22% of the patients.
Regarding the T stage, T1a accounted for 50%, T1b 20%
and T2 around 13%. Thus, over 80% were T2 or less, and
curative surgery is possible for those cases. N1 plus N2
accounted for about 5% of the cases and M1 accounted for
8%. These characteristics may be similar in other institutions
in Japan, but it is unclear whether they are similar in other
Asian countries.
RISK FACTORS
Cigarette smoking, obesity, acquired cystic kidney disease
and inherited susceptibility, such as Von Hippel –Lindau
disease, are established risk factors for kidney cancer
(Table 3) (7,8). Factors that need further study or remain
controversial include dietary factors, such as protein, dietary
fat, a ‘Western’ diet, and inadequate intake of protective
fruits and vegetables. Also in need of further study are poss-
ible roles for hypertension and/or antihypertensive
medications, use of analgesics, reproductive factors and hor-
mones, occupational exposures and inadequate physical
activity (7–9).
TREATMENT OF LOCAL DISEASE
Many guidelines have been established for kidney cancer by
various societies around the world, including the National
Comprehensive Cancer Network (NCCN), EAU and ESMO
(10–12). For treatment of local disease, the NCCN
Guidelines state that surgical excision is the ﬁrst line of treat-
ment for patients with Stage I, II or III kidney cancer (10).
For Stage IV, nephrectomy plus surgical metastasectomy is
recommended for patients with a potentially surgically
resectable, solitary metastatic site. For Stage IV patients
with a potentially surgically resectable primary lesion and
multiple metastatic sites, the recommended treatment is
cytoreductive nephrectomy in select patients prior to sys-
temic therapy. Medical treatment is recommended for surgi-
cally unresectable Stage IV disease. Thus, surgery is the ﬁrst
choice of treatment for local and resectable kidney tumours.
Table 2. Characteristics of Japanese RCC patients who underwent surgical
treatment at Keio University Hospital between 1985 and 2003 (6)
No. patients 545
No. sex: (%)
M 419 (76.9)
F 126 (23.1)
Mean age at diagnosis 58.1
Mean tumour size (cm) 4.82
No. nephrectomy type (%)
Radical 447 (82.0)
Nephron sparing 98 (18.0)
No. adjuvant immunotherapy (%) 121 (22.2)
No. TNM T (%)
T1a 272 (49.9)
T1b 109 (20.0)
T2 69 (12.7)
T3a 56 (10.3)
T3b 30 (5.5)
T3c 2 (0.4)
T4 7 (1.3)
No. TNM N (%)
N0 516 (94.5)
N1 14 (2.6)
N2 15 (2.8)
No. TNM M (%)
M0 499 (91.6)
M1 46 (8.4)
Table 1. Overview of RCC epidemiology (1,2)
Kidney cancer accounts for approximately 2% of all cancers worldwide (1)
Renal cell carcinoma (RCC) is the most common form of kidney cancer (1)
Rates of incidence vary more than 10-fold between regions, with higher
rates in developed nations (2)
Globally the incidence and mortality rates are increasing 2–3% per decade
(2)
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The Japanese Uralogical Association Guidelines also
provide an algorithm for the management of local tumours
(Table 4) (13). As in the NCCN Guidelines, it is rec-
ommended that T1a, T1b and T2 without metastasis be
treated by partial or radical nephrectomy. The surgery can be
open surgery or laparoscopic. In the case of N1 or T3 stage
disease, nephrectomy plus lymph node dissection and/or
extirpation of tumour emboli is recommended. Thus, again,
surgery is the treatment of ﬁrst choice for local RCC.
There are various advantages and limitations with each
approach to the management of local tumours (Table 5)
(14). In the case of radical nephrectomy, the oncological
effectiveness has been established, and laparoscopic surgery
is possible. However, this treatment presents an increased
risk of chronic kidney disease. In the case of partial
nephrectomy, the oncological effectiveness is similar to that
of radical nephrectomy, it preserves renal function, and in
selected patients it can be performed laparoscopically.
However, with partial nephrectomy there is a slight risk of
postoperative haemorrhage or urinary leak. Recently, some
institutions performed minimally invasive procedures,
including radiofrequency ablation or cryoablation. However,
limitations of such techniques are that their long-term onco-
logical effectiveness has not yet been established and local
recurrence rates are somewhat higher than with open or
laparoscopic surgery. Active surveillance has also become a
management choice, but again, the long-term oncological
outcomes have not yet been established, and patient compli-
ance with follow-up is essential.
SYSTEMIC THERAPY FOR METASTATIC
DISEASE
Kidney cancer patients have been treated with immunother-
apy using IFN-a or IL–2 for more than 20 years. High-dose
IL–2 is administered in other countries, and the objective
response rate (ORR) has been 21–23% (14). A distinguish-
ing feature is that the durable complete response rate has
been 5–7%. Low-dose IL–2 and IFN-a are more popular in
Japan, showing an ORR of 10– 15%. However, if this com-
bination therapy is applied to patients with only lung metas-
tasis, ORR reaches around 40% (15). Meta-analysis has
shown an improvement in the weighted median overall survi-
val (OS) with IFN-a compared with the control (14).
Distinguishing features are that there is no evidence of a
dose–response relationship and no correlation between the
response rate and the OS.
Table 3. Risk factors of RCC (7–9)
Established Needing further study or controversial
Cigarette smoking (7,8) Dietary factors (7–9)
Protein, dietary fat, ‘Western diet’
Vegetables and fruit (protective)
Obesity (7,8) Hypertension and/or antihypertensive
medications (7,9)
Acquired cystic kidney
disease (7)
Analgesics (7)
Inherited susceptibility
(e.g. VHL) (7)
Reproductive factors and hormones (e.g.
parity, oral contraceptives) (7)
Occupational exposures (e.g. asbestos,
cadmium, hydrocarbons, gasoline,
tricholoethylene) (7,8)
Physical activity (protective) (8)
Table 4. Algorithm for the management of local tumour (JUA Guidelines) (13)
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Regarding the prognosis of metastatic RCC patients in the
cytokine era, Naito et al. reported in 2009 that 82% of 1324
metastatic RCC patients underwent cytokine therapy and
showed a median survival of 21 months and a one-year survi-
val rate of 64% (16). These data are considerably better than
the data that have been reported in Western countries.
Moreover, it is noteworthy that 28% of the patients under-
went metastasectomy, so perhaps metastasectomy played an
important role in generating these good results of longer sur-
vival and progression-free survival (PFS).
With regard to systemic therapy for metastatic disease
using molecular-targeted drugs, a treatment algorithm was
reported for RCC in the ASCO meeting (Table 6) (17). For
previously untreated patients with good or intermediate risk,
sunitinib or bevacizumab plus IFN-a was recommended as
the ﬁrst-line therapy, while other options consist of high-dose
IL–2 or sorafenib. For untreated, poor-risk patients, temsiroli-
mus was recommended as the ﬁrst-line therapy, while suniti-
nib was an option. In the case of cytokine-refractory RCC
patients, sorafenib was recommended as the ﬁrst-line therapy,
and sunitinib, bevacizumab plus IFN-a and temsirolimus were
presented as options. For vascular endothelial growth factor
(VEGF)-inhibitor-refractory RCC patients, the ﬁrst-choice in
second line therapy was everolimus. Asian guidelines are now
being updated to include the latest data.
There are now ﬁve molecular-targeted therapies available in
the world. All ﬁve are available in the USA, Korea, Malaysia
and the Philippines, but only sorafenib and sunitinib were
available in Japan as of late 2009. Temsirolimus or everolimus
may be approved in 2010. Clinical data are available for sora-
fenib and sunitinib in terms of the median PFS data from
Asian and Western studies of metastatic RCC. When sunitinib
was used as the ﬁrst-line therapy, the results were almost the
same in Western and Japanese studies, at around 11 months
for the PFS (18,19). As second-line therapies, sorafenib
showed somewhat better median PFS results in Japan com-
pared with the Western data (20,21), but sunitinib again
showed no large difference (19,22). Thus, overall, there is no
large difference in the PFS between Asian and Western data.
In terms of the ORR, Chinese and Japanese studies of sorafe-
nib showed better rates than seen in a Western Phase III trial
(20,21,23). For sunitinib, there were no differences between
the Western and Japanese ORR data (18,19). However, the
Korean rate was quite low, although that study is still ongoing
and may show improvement later (24).
In data from the sunitinib expanded access Programme,
the efﬁcacy of sunitinib was similar in Asian and non–Asian
populations in terms of both the PFS and the OS (Table 7)
(25). However, large differences have been found in the inci-
dences of adverse events with sorafenib and sunitinib in
those populations. For example, the incidence of hand–foot
syndrome with sorafenib was very high in Japanese patients
and even higher in Chinese patients, compared with Western
patients (20,21,23). Hypertension was also much higher
in incidence as an adverse event of sorafenib in Asian
patients compared with Western patients. With sunitinib,
treatment-related hematological adverse events, including
thrombocytopenia and neutropenia, were much more
Table 5. Advantages and limitations of various approaches for the management of local tumour (14)
Advantages Limitations
Radical
nephrectomy
Established oncological effectiveness; can be done
laparoscopically
Increased risk of chronic kidney disease; might predispose to morbid
cardiac events and increased mortality rates
Partial
nephrectomy
Oncological effectiveness similar to radical nephrectomy;
preserves renal function; selective cases can be done
laparoscopically
Small risk of postoperative haemorrhage or urinary leak; complex cases
typically require conventional open surgery
Thermal
ablation
Minimally invasive; repeat ablation possible Long-term oncological effectiveness not established; local recurrence
rates higher than with surgical excision; conventional surgical salvage
occasionally required and can be complicated by ﬁbrotic reaction;
radiographic parameters for success not well established; difﬁcult to
adequately treat tumours .3.5 cm in diameter
Active
surveillance
Morbidity of intervention avoided in most patients, deferred in
others; average growth rates and risk of metastasis seem low
Long-term oncological outcomes not established; most series have
substantial selection bias and limited follow-up; compliance with
follow-up required
Table 6. Algorithm for the treatment of metastatic RCC in ASCO (17)
Treatment status Treatment options
Level I level II
Untreated
Good or intermediate risk Sunitinib
Bevacizumab þ IFN
High-dose IL-2
Sorafenib
Poor risk Temsirolimus Sunitinib
Previously treated
Cytokine Sorafenib Sunitinib
Bevacizumab þ IFN
Temsirolimus
VEGFR inhibitor Everolimus Data lacking
mTOR inhibitor Data lacking Data lacking
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common in Japanese patients (Fig. 1) (18,19). Those events
were also elevated in incidence in Korean patients, and in
Asian patients in the expanded access Programme (24,25).
Sunitinib also showed higher incidences of hand–foot syn-
drome and stomatitis in Asian patients compared with
Western patients (25).
Determination of the blood concentration of sunitinib in
Western and Asian populations revealed that the concen-
tration of this tends to be higher in Asians, in females and
exaggerated in Asian females (26).
Bevacizumab is an antibody directed at VEGF protein,
and combination of bevacizumab plus IFN-a shows a better
ORR and OS compared with IFN-a (27,28). Temsirolimus
shows signiﬁcantly better PFS and OS than those with
IFN-a in the poor-risk patients (29). Everolimus targeted
RCC patients refractory to sorafenib, sunitinib or both (30).
Therefore, ORR was quite low and PFS period was also
short. Nevertheless, the results were still signiﬁcantly better
than those with the placebo. It is on the basis of such results
that these three molecular-targeted agents are available in
the world.
CONSENSUS STATEMENT
In terms of epidemiology, kidney cancer is relatively uncom-
mon in Asia compared with the West. However, the inci-
dence is increasing in more developed Asian nations. As
more Asian nations develop economically and become more
Westernized, along with the higher rates of smoking and the
growing problem of obesity in Asia, it can be foreseen that
the incidence of kidney cancer will continue to approach that
in the West. Increased use of imaging techniques has con-
tributed to an increase in incidental kidney cancer and early
discovery of kidney cancer. For treatment of kidney cancer,
guidelines from the NCCN, EAU, ESMO and other organiz-
ations have been developed based on Phase III clinical trials
that were conducted primarily in Western patients. Targeted
therapies are now the primary recommended treatments of
choice for metastatic RCC. However, cytokines are still
more widely used in some Asian countries and have been
proved to be effective in selected patient populations, such
as those with only lung metastasis. There is a need for more
Asian clinical data. Because the pivotal trials demonstrating
the beneﬁt of targeted therapies were conducted primarily in
the Western world, there is a lack of efﬁcacy and/or toxicity
data for most of those therapies in Asian patients. Some
drugs are known for their adverse effects resulting from rec-
ommended dosages that are optimal for Caucasian patients
but may be too high for Asian patients, possibly due to
lower body surface area, or genetic and pharmacological
differences. It is recommended that targeted drugs be investi-
gated further in Asian populations to develop an optimal
treatment strategy for kidney cancer in Asians in accordance
with pharmacogenetic information, efﬁcacy and tolerability.
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